LY96 antibody (Lymphocyte Antigen 96)

Details for Product anti-LY96 Antibody No. ABIN2192085, Supplier: Log in to see
Antigen
  • MD2
  • ESOP-1
  • MD-2
  • ly-96
  • Ly-96
  • Md2
  • lymphocyte antigen 96
  • LY96
  • Ly96
Alternatives
anti-Human LY96 antibody for Immunohistochemistry (Frozen Sections)
Reactivity
Human
111
42
26
1
1
1
1
1
Host
Mouse
83
35
Clonality (Clone)
Monoclonal ()
Conjugate
This LY96 antibody is un-conjugated
11
11
3
2
2
2
Application
Flow Cytometry (FACS), Inhibition Assay (InhA)
104
49
48
15
12
5
5
5
5
4
3
2
2
1
Options
Supplier
Log in to see
Supplier Product No.
Log in to see
Immunogen TLR4/MD-2 expressing CHO cells/ chimeric TLR4/MD-2 fusion protein
Clone 18H10
Sterility 0.2 μm filtered
Plasmids, Primers & others Plasmids, Primers & others LY96 products on genomics-online (e.g. as negative or positive controls)
Antigen
Alternative Name Md-2 (LY96 Antibody Abstract)
Background The monoclonal antibody 18H10 reacts with MD-2, an accessory molecule of the Toll-like receptor 4 (TLR4, CD284). TLRs belong to a family of proteins that specifically recognizes and senses microbial products. They are highly conserved throughout evolution and act as innate immune recognition receptors against many pathogens. TLR4 is a functional receptor for gram-negative bacterial lipopolysaccharides (LPS). TLR4 associates with MD-2 which is absolutely required for LPS-induced activation of TLR4. MD-2 exists as a cell surface protein in association with TLR4. It also exists as secreted forms consisting of MD-2 monomers and multimers (sMD-2). Circulating sMD-2 is mainly present as a doublet of ~20 and 25 kD, representing differentially glycosylated forms. Unlike TLR4, sMD-2 binds directly LPS without the need of soluble CD14 (sCD14). However, LPS-MD-2 interactions are increased when LPS is pretreated with CD14. Only monomeric sMD-2 is biologically active and able to associate with TLR4 and LPS. sMD-2 circulates in plasma of healthy individuals as a non-active, polymeric protein. In septic plasma, the total amount of sMD-2 was strongly elevated and contained both sMD-2 polymers and monomers. Soluble MD-2 is proposed to be an important mediator of organ inflammation during sepsis. During experimental human endotoxemia, the monomeric and total sMD-2 content in plasma increased with the kinetics of an acute phase protein. This parallels enhanced TLR4 costimulatory activity. In vitro studies revealed that sMD-2 release appears to be restricted to endothelial and dendritic cells. The monoclonal antibody 18H10 reacts with MD-2. However, it does not react with sMD-2. In addition, the monoclonal antibody 18H10 is able to inhibit bacterial binding to MD-2. Aliases Lymphocyte antigen 96, ESOP-1, LY96
Pathways TLR Signaling, Activation of Innate immune Response, Cellular Response to Molecule of Bacterial Origin, Toll-Like Receptors Cascades
Application Notes For flow cytometry, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, dilutions have to be made according to the amounts of MD-2 to be inactivated.
Restrictions For Research Use only
Buffer PBS, containing 0.1 % bovine serum albumin.
Storage 4 °C
Storage Comment Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.
Expiry Date 12 months
Product cited in: Tissières, Dunn-Siegrist, Schäppi, Elson, Comte, Nobre, Pugin: "Soluble MD-2 is an acute-phase protein and an opsonin for Gram-negative bacteria." in: Blood, Vol. 111, Issue 4, pp. 2122-31, 2008 (PubMed).

Daubeuf, Mathison, Spiller, Hugues, Herren, Ferlin, Kosco-Vilbois, Wagner, Kirschning, Ulevitch, Elson: "TLR4/MD-2 monoclonal antibody therapy affords protection in experimental models of septic shock." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 179, Issue 9, pp. 6107-14, 2007 (PubMed).

Elson, Dunn-Siegrist, Daubeuf, Pugin: "Contribution of Toll-like receptors to the innate immune response to Gram-negative and Gram-positive bacteria." in: Blood, Vol. 109, Issue 4, pp. 1574-83, 2007 (PubMed).

Pugin, Stern-Voeffray, Daubeuf, Matthay, Elson, Dunn-Siegrist: "Soluble MD-2 activity in plasma from patients with severe sepsis and septic shock." in: Blood, Vol. 104, Issue 13, pp. 4071-9, 2004 (PubMed).

Did you look for something else?